{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Nielsen CM"],"funding":["European Seventh Framework","Medical Research Council","United States Agency for International Development","Wellcome Trust"],"pagination":["e163859"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9977309"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(2)"],"pubmed_abstract":["Modifications to vaccine delivery that increase serum antibody longevity are of great interest for maximizing efficacy. We have previously shown that a delayed fractional (DFx) dosing schedule (0-1-6 month) - using AS01B-adjuvanted RH5.1 malaria antigen - substantially improves serum IgG durability as compared with monthly dosing (0-1-2 month; NCT02927145). However, the underlying mechanism and whether there are wider immunological changes with DFx dosing were unclear. Here, PfRH5-specific Ig and B cell responses were analyzed in depth through standardized ELISAs, flow cytometry, systems serology, and single-cell RNA-Seq (scRNA-Seq). Data indicate that DFx dosing increases the magnitude and durability of circulating PfRH5-specific B cells and serum IgG1. At the peak antibody magnitude, DFx"],"journal":["JCI insight"],"pubmed_title":["Delayed boosting improves human antigen-specific Ig and B cell responses to the RH5.1/AS01B malaria vaccine."],"pmcid":["PMC9977309"],"funding_grant_id":["106917/Z/15/Z","AID-OAA-C-15-00071","209200/Z/17/Z","FP7/2007-2013","MR/K025554/1"],"pubmed_authors":["Miura K","Lauffenburger DA","Douek DC","Minassian AM","Griffin C","Alter G","Nielsen CM","Barrett JR","Davis C","Goh C","Long CA","Laboune F","Fallon JK","Silk SE","Francica JR","Loos C","Darko S","Michell AR","Payne RO","Seder RA","Tekman M","Kwok A","Diouf A","Ransier A","Draper SJ"],"additional_accession":[]},"is_claimable":false,"name":"Delayed boosting improves human antigen-specific Ig and B cell responses to the RH5.1/AS01B malaria vaccine.","description":"Modifications to vaccine delivery that increase serum antibody longevity are of great interest for maximizing efficacy. We have previously shown that a delayed fractional (DFx) dosing schedule (0-1-6 month) - using AS01B-adjuvanted RH5.1 malaria antigen - substantially improves serum IgG durability as compared with monthly dosing (0-1-2 month; NCT02927145). However, the underlying mechanism and whether there are wider immunological changes with DFx dosing were unclear. Here, PfRH5-specific Ig and B cell responses were analyzed in depth through standardized ELISAs, flow cytometry, systems serology, and single-cell RNA-Seq (scRNA-Seq). Data indicate that DFx dosing increases the magnitude and durability of circulating PfRH5-specific B cells and serum IgG1. At the peak antibody magnitude, DFx","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2026-05-28T08:08:52.424Z","creation":"2025-04-25T17:11:56.077Z"},"accession":"S-EPMC9977309","cross_references":{"pubmed":["36692019"],"doi":["10.1172/jci.insight.163859"]}}